Issued 2026-08-13 at $104.09 · now $101.85 (2026-08-13, −2.2% since)
Based on its own history, a month from the 2026-08-13 close, SYRE has typically landed between $65.52 and $164.16 — a range of −37.1% to +57.7% from the issuance price $104.09.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
2,578 overlapping 1 month windows · 2016-04-07 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($104.09) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where SYRE has typically landed a month from the 2026-08-13 close of $104.09 — the range is history, not a prediction.
- now $101.85 (-2.2%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $103.58 (-0.5%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $85.93–$121.22
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $65.52–$164.16
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2022-11-10 | −74.7% | −75.6% | +0.0% |
| 2022-11-11 | −71.9% | −72.6% | +0.0% |
| 2022-11-16 | −71.9% | −71.9% | +0.0% |
| 3 best | |||
| 2023-06-21 | +456.6% | +0.0% | +538.5% |
| 2023-06-14 | +366.1% | −27.0% | +366.1% |
| 2023-06-15 | +334.8% | −28.0% | +359.8% |
2,578 overlapping windows · 2016-04-07 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-10-31 — Trial primary completion: Phase 2 primary completion: A Study of SPY072 in Rheumatic Disease (source, as of 2026-08-14)
- June 2027 — Trial primary completion: Phase 2 primary completion: A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis (source, as of 2026-08-14)
- 2029-03-02 — Trial primary completion: Phase 2 primary completion: Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~11 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.